financetom
Business
financetom
/
Business
/
Extra Space Storage reports upbeat first-quarter results amid high occupancy rates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Extra Space Storage reports upbeat first-quarter results amid high occupancy rates
May 25, 2025 9:20 PM

April 29 (Reuters) - Extra Space Storage ( EXR ) beat

Wall Street expectations for first-quarter revenue and funds

from operations (FFO) on Tuesday, driven by high occupancy rates

and the expansion of its low-capital business lines.

The Salt Lake City, Utah-based real estate investment trust

(REIT) reported total revenue of $819.9 million for the quarter

ended March 31, up from $799.5 million in the same period a year

earlier. On average, analysts expected revenue of $763.5 million

in the quarter, according to data compiled by LSEG.

As part of its capital-light ancillary businesses, the

company offers services such as third-party management of

storage properties, tenant insurance programs and data services,

among others.

The self-storage operator expects its FFO for 2025 to be in

a range of $8 to $8.3 per share, with the mid-point exceeding

analysts' estimates of $8.2 per share.

The company may benefit from increased demand as importers

and retailers frontload shipments in anticipation of

tariff-related price hikes, driving the need for flexible,

short-term storage solutions.

The REIT's same-store occupancy rate for the quarter stood

at 93.4%, compared to 92.4% in the same period last year.

"The recent economic uncertainty has caused us to maintain

our same-store guidance. While the current environment is

volatile and may lead to difficult economic times," said CEO Joe

Margolis.

The company reported a core FFO of $2 per share for the

quarter, surpassing analysts' estimates of $1.98 per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cenovus Energy Price Target Raised at ATB, Desjardins
Cenovus Energy Price Target Raised at ATB, Desjardins
Aug 25, 2025
08:46 AM EDT, 08/25/2025 (MT Newswires) -- Analysts at ATB Capital Markets and Desjardins raised their price targets on Cenovus Energy Inc. ( CVE ) to $28 from $25, and to $29 from $27.50, respectively. ATB analyst Patrick J. O'Rourke maintained an Outperformer rating on shares of the Calgary-based integrated oil and gas company following its August 22 announcement that...
SLB's OneSubsea JV Obtains Equinor Offshore Contract
SLB's OneSubsea JV Obtains Equinor Offshore Contract
Aug 25, 2025
08:50 AM EDT, 08/25/2025 (MT Newswires) -- SLB (SLB) said Monday that its OneSubsea joint venture was awarded an engineering, procurement, and construction contract by Equinor ( EQNR ) for a 12-well, electric subsea production system off the coast of Norway. Financial details weren't disclosed. OneSubsea is a joint venture between SLB, engineering and services firm Aker Solutions, and offshore...
POET Technologies to Delist From TSX Venture Exchange
POET Technologies to Delist From TSX Venture Exchange
Aug 25, 2025
08:53 AM EDT, 08/25/2025 (MT Newswires) -- POET Technologies ( POET ) said Monday it will proceed with a previously announced voluntary delisting of its shares from the TSX Venture Exchange while keeping its Nasdaq Capital Market listing. The company said it has received approval for the delisting which is expected to take effect after markets close on Wednesday. POET...
Catalyst Pharmaceuticals Says Settlement Reached With Lupin Pharmaceuticals in Firdapse Patent Litigation
Catalyst Pharmaceuticals Says Settlement Reached With Lupin Pharmaceuticals in Firdapse Patent Litigation
Aug 25, 2025
08:52 AM EDT, 08/25/2025 (MT Newswires) -- Catalyst Pharmaceuticals ( CPRX ) and its licensor SERB have reached a settlement agreement with Lupin Pharmaceuticals to resolve patent litigation brought by Catalyst against Lupin's Abbreviated New Drug Application to market a generic version of Catalyst's Firdapse prior to expiration of the applicable patents, Catalyst said Monday. Under terms of the settlement,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved